Serious infections and cardiovascular complications among patients with chronic lymphocytic lymphoma treated with first-line ibrutinib or bendamustine/rituximab.

被引：0
|
作者：
Irwin, Debra E.
Thompson, Stephen
Ribalov, Rinat
Choudhry, Azhar
机构：
[1] IBM Watson Hlth, Cambridge, MA USA
[2] Teva Pharmaceut Inc, Parsippany, NJ USA
[3] Teva Pharmaceut Ind LTD, Petah Tiqwa, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19503
引用
收藏
页数：3
相关论文
共 50 条
  • [31] INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA TREATED WITH IBRUTINIB
    Wasik-Szczepanek, E.
    Szymczyk, A.
    Czabak, O.
    Cioch, M.
    Wach, M.
    Podhorecka, M.
    Sokolowska, B.
    Pasiarski, M.
    Kozinska, J.
    Hus, I.
    Szczepanek, D.
    Kotwica, K.
    Szczepanek, A.
    Hus, M.
    HAEMATOLOGICA, 2017, 102 : 722 - 722
  • [32] Role of rituximab in first-line treatment of chronic lymphocytic leukemia
    Bryan, Jeffrey
    Borthakur, Gautam
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2011, 7 : 1 - 11
  • [33] Combination of ibrutinib and venetoclax in first-line treatment of chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2022, 28 (01): : 12 - 13
  • [34] Combination Trial of Duvelisib (IPI-145) with Bendamustine, Rituximab, or Bendamustine/Rituximab in Patients with Lymphoma or Chronic Lymphocytic Leukemia
    Flinn, Ian W.
    Cherry, Mohamad
    Maris, Michael
    Matous, Jeffrey V.
    Berdeja, Jesus G.
    Patel, Manish R.
    BLOOD, 2015, 126 (23)
  • [35] FIRST LINE TREATMENT WITH BENDAMUSTINE-RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA
    Buenasmananas Cervantes, D.
    Calle Primo, C.
    Nebro Luque, M. dM
    Hernandez Ruiz, B.
    HAEMATOLOGICA, 2015, 100 : 266 - 266
  • [36] Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study
    Stadnik, E. A.
    Strugov, V. V.
    Andreeva, T. O.
    Virts, Yu. V.
    Rumyantsev, A. M.
    Mirolyubova, Yu. V.
    Butylin, P. A.
    Zaritsky, A. Yu.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 57 - 64
  • [37] Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
    Jacobs, Ryan
    Lu, Xiaoxiao
    Emond, Bruno
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Khan, Wasiulla
    Wu, Linda H.
    Qureshi, Zaina P.
    Levy, Moshe Yair
    FUTURE ONCOLOGY, 2024, 20 (01) : 39 - 53
  • [38] IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY
    Cramer, P.
    Chanan-Khan, A.
    Demirkan, F.
    Fraser, G.
    Santucci Silva, R.
    Pylypenko, H.
    Grosicki, S.
    Janssens, A.
    Pristupa, A.
    Mayer, J.
    Dilhuydy, M. S.
    Loscertales, J.
    Bartlett, N. L.
    Avigdor, A.
    Rule, S.
    Sun, S.
    Mahler, M.
    Salman, M.
    Howes, A.
    Hallek, M.
    HAEMATOLOGICA, 2015, 100 : 55 - 56
  • [39] Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab
    Chanan-Khan, Asher
    Cramer, Paula
    Demirkan, Fatih
    Fraser, Graeme
    Silva, Rodrigo Santucci
    Pylypenko, Halyna
    Grosicki, Sebastian
    Janssens, Ann
    Pristupa, Aleksander
    Goy, Andre
    Mayer, Jiri
    Dilhuydy, Marie Sarah
    Loscertales, Javier
    Bartlett, Nancy L.
    Avigdor, Abraham
    Rule, Simon
    Sun, Steven
    Phelps, Charles
    Mahler, Michelle
    Salman, Mariya
    Howes, Angela
    Hallek, Michael
    BLOOD, 2015, 126 (23)
  • [40] The value of bendamustine dose and cycles, sIL-2R, and LDH in follicular lymphoma patients treated with bendamustine plus rituximab.
    Jo, Tatsuro
    Matsuo, Masatoshi
    Taguchi, Jun
    Abe, Kuniko
    Shigematsu, Kazuto
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345